References
- Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. Curr Med Res Opin 2015; 32(2);301-311
- Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010;376:540-50
- Food and Drug Administration. Lovaza: GlaxoSmithKline. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021654s034lbl.pdf [Last Accessed 13 December 2015]
- Electronic Medicines Compendium. Omacor: Abbott Healthcare Products Limited. Available at: http://www.medicines.org.uk/emc/medicine/10312/indications [Last accessed 13 December 2015]
- Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33
- Bonds DE, Harrington M, Worrall BB, et al,; Writing Group for the AREDS2 Research Group. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med 2014;174:763-71
- Macchia A, Grancelli H, Varini S, et al.; GESICA Investigators. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll Cardiol 2013;61:463-8
- Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. Risk and Prevention Study Collaborative Group. N Engl J Med 2013;368:1800-8
- Rizos EC, Ntzani EE. ω-3 fatty acids and lutein + zeaxanthin supplementation for the prevention of cardiovascular disease. JAMA Intern Med 2014;174:771-2
- Rizzo M, Barylski M, Rizvi AA, et al. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des 2013;19:3858-68
- Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45
- Landray MJ, Haynes R, Hopewell JC, et al.; HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12